Intercept Pharmaceuticals buy Quitte
Summary
This prediction ended on 15.08.16 with a price of €144.84. With a performance of 36.86% the BUY prediction by Quitte was a big success. Quitte has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Intercept Pharmaceuticals | - | - | - | - |
iShares Core DAX® | 2.594% | -1.158% | 14.782% | 16.813% |
iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% | 44.227% |
iShares Nikkei 225® | 0.687% | -8.354% | 18.454% | 1.361% |
iShares S&P 500 | 2.209% | -0.942% | 31.361% | 42.812% |
Comments by Quitte for this prediction
In the thread Intercept Pharmaceuticals diskutieren
Gerüchteküche
What: Shares ofIntercept Pharmaceuticals (NASDAQ:ICPT),a clinical stage biopharmaceutical company focused on treatingdiseases of the liver and intestines, jumped more than 27% as of 2:45p.m. EST Friday after Reuters reported that the company might belooking to sell itself.
So what: According to "sources familiarwith the matter" Intercept has been working with a group ofinvestment bankers recently to "explore the prospect of a sale."
It should be emphasized that this is still a rumor at this pointas Intercept declined to comment.
Now what: This isn't the first time that rumorshave floated around that Intercept might be a buyout target asroughly a year ago another reported surfaced saying that the companycould action itself off as it received interest from a handful oflarge pharma companies that including Gilead Sciences(NASDAQ:GILD).
If Friday's rumors do prove to be true, then Gilead Sciences mightbe an idealacquirer for Intercept as it already has a strong position theliver disease markets, so Intercept could be an interesting strategicfit. It's also worth remembering that Gilead Sciences ended 2015 with$26.2 billion in cash, so it has plenty of capital to make anacquisition if it choose to. For comparison, even with today's popIntercept's current market value is roughly $3 billion.